Yang L, Xu H Y, Wang Y
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhonghua Zhong Liu Za Zhi. 2020 Apr 23;42(4):292-295. doi: 10.3760/cma.j.cn112152-20200229-00152.
With the increasing number of cases and widening geographical spread, the 2019 novel coronavirus disease (COVID-19) has been classified as one of the class B infectious diseases but prevented and controlled as class A infectious disease by the National Health Commission of China. The diagnosis and treatment of lung cancer patients have been challenged greatly because of extraordinary public health measures since the lung cancer patients are a high-risk population during the COVID-19 outbreak period. Strict protection for lung cancer patients is needed to avoid infection. Lung cancer patients are difficult to differentiate from patients with COVID-19 in terms of clinical symptoms, which will bring great trouble to the clinical work and physical and mental health of lung cancer patients. This review will demonstrate how to applicate appropriate and individual management for lung cancer patients to protect them from COVID-19.
随着病例数量的增加和地域传播范围的扩大，新型冠状病毒肺炎（COVID-19）已被中国国家卫生健康委员会列为乙类传染病，但采取甲类传染病的预防、控制措施。由于自COVID-19疫情爆发以来采取了特殊的公共卫生措施，肺癌患者的诊断和治疗受到了极大挑战，因为肺癌患者在COVID-19疫情期间属于高危人群。需要对肺癌患者进行严格保护以避免感染。肺癌患者在临床症状方面难以与COVID-19患者区分开来，这将给肺癌患者的临床工作以及身心健康带来极大困扰。本综述将阐述如何对肺癌患者采取适当的个体化管理措施以保护他们免受COVID-19感染。
